XCYTON DIAGNOSTICS PRIVATE LIMITED

Bengaluru-based XCyton Diagnostics generated revenue worth Rs 10.7 crore during FY 20-21, growing by almost 2.5x when compared to the revenue generation of Rs 3.9 crore in the previous fiscal. Founded in 1993, XCyton has developed many immunodiagnostic kits for the detection of infections. XCyton is credited with the development of the first indigenous ELISA kit for the detection of HIV infection called HIV CheX, following with the development of indigenous ELISA products for the detection of Hepatitis C (HEP CheX C), Neurocysticercosis (CYSTI CheX) and Japanese encephalitis (JEV CheX). The company has developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System.